BrightPath Biotherapeutics , Ltd. Receivables

BrightPath Biotherapeutics , Ltd. (4594.T) currently reports a receivables of $12K as of June 2026. That compares with $36K in the prior-year period — down 66.7% year over year. Use the charts on this page to explore BrightPath Biotherapeutics , Ltd.'s receivables history and peer comparisons.

BrightPath Biotherapeutics , Ltd.'s receivables decreased from $36K to $12K — a 66.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BrightPath Biotherapeutics , Ltd. reported $12K in receivables as of June 2026. That compares with $36K in the prior-year period — down 66.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $12K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BrightPath Biotherapeutics , Ltd., and consider following 4594.T for alerts when major investors trade the stock.

BrightPath Biotherapeutics , Ltd. is classified in the Healthcare sector. On receivables, it currently shows $12K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 4594.T with unrelated industries.